PRA buys out Takeda JV in Japan

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)
PRA Health Sciences has bought out its joint venture with Takeda, establishing a new subsidiary based in Japan – a rapidly growing market, says EVP.

PRA Health Sciences K.K. is now operating as a PRA subsidiary in Japan following PRA Health Sciences buyout of its joint venture with Takeda Pharmaceutical Company Limited, which was established in 2017.

The addition of Takeda’s staff increases PRA’s totals employee numbers to 450 in Japan, with the opportunity for additional growth in the near term, according to the company.

Including the PRA’s new offices in Tokyo and Osaka, the company currently has more than 2,300 staff members across 15 countries in the Asia region.

“Our vision is to be the premier pharma partner in Japan by expanding our operations and expertise across therapeutic areas and functions to serve Japan and the entire Asia Pacific region,”​ said Samir Shah, executive vice president and president, strategic solutions at PRA Health Sciences.

“Asia is the third largest market for biopharmaceutical outsourcing, and Japan is rapidly growing. PRA has made an investment in the region reflective of the business opportunity,”​ he told us.

As for integration, Dr. Atsushi Ogawa, president and representative director of PRA Japan, said the process is progressing “steadily and smoothly.” ​The company is already conducting in-house work and providing services to clients, including Takeda, he told us.

“PRA Japan provides flexible infrastructure, end-to-end clinical development across all phases, embedded solutions, and technology and data science,”​ Ogawa added.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars